Enlivex: Surges on positive data from potential COVID-19 treatment

Enlivex

01/10/2020 12:10

** U.S.-listed shares of Israel-based drug developer
 ENLV.O  up 62.5% to ~$10 premarket; set for their best day ever
    ** Stock also set to touch its highest in 7 months and erase
its YTD losses, if gains hold
    ** Co says study shows all five severe and critical COVID-19
patients completely recovered after taking its treatment,
Allocetra, an experimental therapy also being tested to treat
patients with organ failure associated with sepsis 
    ** All 5 patients were released from hospital after an
average of 5.5 days (severe patients) and 8.5 days (critical
patients), following administration of Allocetra
    ** Co says based on data from two studies, it will shift
recruitment of additional patients from investigator-initiated
trial into larger mid-stage trial of COVID-19 patients as soon
as possible 
    ** ENLV says initial positive results seen in sepsis
patients treated with Allocetra are consistent with those
observed in COVID-19 patients in severe and critical condition

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))